AACR: Pieris releases positive new data on cinrebafusp in gastric cancer

Shares of US clinical-stage biotech Pieris Pharmaceuticals (Nasdaq: PIRS) were in 6% at $0.76 in pre-market trading today as the company announced the presentation of cinrebafusp alfa (PRS-343) clinical results in 2L+ HER2-positive gastric cancer at the American Association for Cancer Research annual meeting being held in Orlando, Florida on April 14-19, 2023.

The encouraging results include an unconfirmed 100% objective response rate and promising emerging durability profile in the five patients enrolled into the study before discontinuation of enrollment for strategic reasons.

"The power and potential of both cinrebafusp alfa and the 4-1BB franchise can be seen in this exciting signal," stated Shane Olwill, chief development officer of Pieris. "The ability to drive response in patients who progressed on the most potent currently available therapies provides further evidence of the differentiation of cinrebafusp alfa in the HER2 landscape as well as the overall 4-1BB franchise. Beyond cinrebafusp alfa, we look forward to the progression of-and future data read-outs for-the broader 4-1BB franchise, including our PD-L1/4-1BB bispecific in collaboration with Servier in Phase I studies, our CD228/4-1BB bispecific with Seagen [Nasdaq: SEGN] in Phase I studies, and our GPC-3/4-1BB bispecific with Boston Pharmaceuticals entering the clinic shortly."